Overview
Final Chapter: Post-COVID-19 Fibrosis and the Role of Antifibrotic Therapy Management
COVID-19 and Pulmonary Fibrosis Vlog
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
• post-ARDS fibrosis in patients who have recovered from COVID-19
• the potential role of antifibrotic therapies
• ongoing clinical trials
• Identify the current clinical data on the potential development of progressive pulmonary fibrosis in patients recovering from COVID-19-induced acute lung injury and ARDS
• Outline emerging approaches to treating patients with COVID-19-related acute lung injury and ARDS
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problems
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Director, Transplant and Advanced Lung Disease Critical Care Program
Inova Fairfax Hospital
Assistant Clinical Professor
Virginia Commonwealth University
Falls Church, VA
Discussion of off-label, Investigational, or Experimental Drug/Device Use: dexamethasone and other treatments not yet approved to treat COVID-19.